Topotecan

Drug Profile

Topotecan

Alternative Names: Hycamtin; NK-211; Nogitecan; NSC 609699; SKF 104864; Topotecan hydrochloride

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Nippon Kayaku; Novartis; SCRI Development Innovations
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
  • Phase III Brain cancer

Most Recent Events

  • 18 Feb 2016 Investigation in Small cell lung cancer (Combination therapy) in USA (PO)
  • 18 Feb 2016 Phase-I/II clinical trials in Ovarian cancer (Combination therapy) in USA (PO)
  • 02 Mar 2015 Novartis acquires Topotecan from GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top